JPWO2019226761A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226761A5 JPWO2019226761A5 JP2020565359A JP2020565359A JPWO2019226761A5 JP WO2019226761 A5 JPWO2019226761 A5 JP WO2019226761A5 JP 2020565359 A JP2020565359 A JP 2020565359A JP 2020565359 A JP2020565359 A JP 2020565359A JP WO2019226761 A5 JPWO2019226761 A5 JP WO2019226761A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- pharmaceutical composition
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093659A JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675639P | 2018-05-23 | 2018-05-23 | |
| US62/675,639 | 2018-05-23 | ||
| PCT/US2019/033505 WO2019226761A1 (en) | 2018-05-23 | 2019-05-22 | Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Division JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525248A JP2021525248A (ja) | 2021-09-24 |
| JPWO2019226761A5 true JPWO2019226761A5 (xx) | 2022-05-30 |
| JP7293256B2 JP7293256B2 (ja) | 2023-06-19 |
Family
ID=66999900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565359A Active JP7293256B2 (ja) | 2018-05-23 | 2019-05-22 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11439637B2 (xx) |
| EP (2) | EP3796912B1 (xx) |
| JP (2) | JP7293256B2 (xx) |
| KR (1) | KR20210021996A (xx) |
| CN (2) | CN112399848B (xx) |
| AU (1) | AU2019274530B2 (xx) |
| BR (1) | BR112020023704A2 (xx) |
| CA (1) | CA3101050A1 (xx) |
| CY (1) | CY1126060T1 (xx) |
| DK (1) | DK3796912T5 (xx) |
| EA (1) | EA202092830A1 (xx) |
| ES (1) | ES2945214T3 (xx) |
| FI (1) | FI3796912T3 (xx) |
| HR (1) | HRP20230449T1 (xx) |
| HU (1) | HUE061792T2 (xx) |
| IL (1) | IL278853A (xx) |
| LT (1) | LT3796912T (xx) |
| MX (1) | MX2020012485A (xx) |
| PL (1) | PL3796912T3 (xx) |
| PT (1) | PT3796912T (xx) |
| RS (1) | RS64189B1 (xx) |
| SG (1) | SG11202011545YA (xx) |
| SI (1) | SI3796912T1 (xx) |
| WO (1) | WO2019226761A1 (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019272751B2 (en) | 2018-05-23 | 2024-08-15 | Celgene Corporation | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile |
| CN114394954B (zh) * | 2019-01-09 | 2024-04-02 | 细胞基因公司 | 包含氧代异吲哚化合物及其盐的固体形式，以及包含它们的组合物和它们的使用方法 |
| CN113597301A (zh) * | 2019-01-09 | 2021-11-02 | 细胞基因公司 | 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法 |
| CN118178417A (zh) * | 2019-01-09 | 2024-06-14 | 细胞基因公司 | 用于治疗多发性骨髓瘤的抗增殖化合物和第二活性剂 |
| EP4095132A1 (en) * | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| AU2021263765A1 (en) * | 2020-04-28 | 2022-12-01 | Juno Therapeutics, Inc. | Combination of BCMA-directed T cell therapy and an immunomodulatory compound |
| AU2021263408A1 (en) | 2020-04-30 | 2022-10-27 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20240277844A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
| ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| PL3283106T3 (pl) | 2015-04-13 | 2022-05-02 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| RS60030B1 (sr) | 2015-08-03 | 2020-04-30 | Engmab Sarl | Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma) |
| US10238225B2 (en) * | 2016-06-08 | 2019-03-26 | Windor Enterprises, LLC | Compression garment donning aid device, method, and kit |
| US11331380B2 (en) | 2016-10-20 | 2022-05-17 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
| BR112020000442A2 (pt) * | 2017-07-10 | 2020-07-21 | Celgene Corporation | compostos antiproliferativos e métodos de uso dos mesmos |
-
2019
- 2019-05-22 HR HRP20230449TT patent/HRP20230449T1/hr unknown
- 2019-05-22 BR BR112020023704-3A patent/BR112020023704A2/pt unknown
- 2019-05-22 EP EP19732494.0A patent/EP3796912B1/en active Active
- 2019-05-22 AU AU2019274530A patent/AU2019274530B2/en active Active
- 2019-05-22 LT LTEPPCT/US2019/033505T patent/LT3796912T/lt unknown
- 2019-05-22 RS RS20230351A patent/RS64189B1/sr unknown
- 2019-05-22 MX MX2020012485A patent/MX2020012485A/es unknown
- 2019-05-22 PT PT197324940T patent/PT3796912T/pt unknown
- 2019-05-22 WO PCT/US2019/033505 patent/WO2019226761A1/en unknown
- 2019-05-22 EA EA202092830A patent/EA202092830A1/ru unknown
- 2019-05-22 SI SI201930535T patent/SI3796912T1/sl unknown
- 2019-05-22 JP JP2020565359A patent/JP7293256B2/ja active Active
- 2019-05-22 ES ES19732494T patent/ES2945214T3/es active Active
- 2019-05-22 CN CN201980046500.XA patent/CN112399848B/zh active Active
- 2019-05-22 SG SG11202011545YA patent/SG11202011545YA/en unknown
- 2019-05-22 KR KR1020207036733A patent/KR20210021996A/ko unknown
- 2019-05-22 DK DK19732494.0T patent/DK3796912T5/da active
- 2019-05-22 FI FIEP19732494.0T patent/FI3796912T3/fi active
- 2019-05-22 CN CN202110586843.4A patent/CN113713095A/zh active Pending
- 2019-05-22 US US16/419,971 patent/US11439637B2/en active Active
- 2019-05-22 EP EP23156579.7A patent/EP4218762A3/en active Pending
- 2019-05-22 HU HUE19732494A patent/HUE061792T2/hu unknown
- 2019-05-22 CA CA3101050A patent/CA3101050A1/en active Pending
- 2019-05-22 PL PL19732494.0T patent/PL3796912T3/pl unknown
-
2020
- 2020-11-20 IL IL278853A patent/IL278853A/en unknown
-
2022
- 2022-08-17 US US17/820,534 patent/US12053466B2/en active Active
-
2023
- 2023-05-15 CY CY20231100227T patent/CY1126060T1/el unknown
- 2023-06-07 JP JP2023093659A patent/JP7550922B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3796912T3 (fi) | Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| CN109071646A (zh) | TGFβ1-结合免疫球蛋白及其用途 | |
| US20200002428A1 (en) | Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody | |
| JPWO2019226761A5 (xx) | ||
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP2014508782A5 (xx) | ||
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| JP2014500278A5 (xx) | ||
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| JP2014525926A5 (xx) | ||
| JP2018533569A5 (xx) | ||
| JP2020532562A5 (xx) | ||
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JP2013504603A5 (xx) | ||
| EP3630177B1 (en) | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment | |
| JP2023011549A5 (xx) | ||
| JP2013523867A5 (xx) | ||
| JP2020507569A5 (xx) | ||
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JPWO2019165237A5 (xx) | ||
| JP2007510661A5 (xx) | ||
| US20240307484A1 (en) | Method for treating triple-negative breast cancer or metastasis thereof with pharmaceutical composition | |
| JPWO2021093839A5 (xx) |